EP1190722A2 - Pansement - Google Patents

Pansement Download PDF

Info

Publication number
EP1190722A2
EP1190722A2 EP01120367A EP01120367A EP1190722A2 EP 1190722 A2 EP1190722 A2 EP 1190722A2 EP 01120367 A EP01120367 A EP 01120367A EP 01120367 A EP01120367 A EP 01120367A EP 1190722 A2 EP1190722 A2 EP 1190722A2
Authority
EP
European Patent Office
Prior art keywords
polyurethane
adhesive
adhesive layer
und
dressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01120367A
Other languages
German (de)
English (en)
Other versions
EP1190722B1 (fr
EP1190722A3 (fr
Inventor
Helge Ahrens
Carsten Hartkopf
Jochen Dr. Kenndoff
Ulrich Dr. Köhler
Dirk Dr. Lenz
Robert Dr. Mayan
Günther Sachau
Ingrid Wesselkamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7657689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1190722(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1190722A2 publication Critical patent/EP1190722A2/fr
Publication of EP1190722A3 publication Critical patent/EP1190722A3/fr
Application granted granted Critical
Publication of EP1190722B1 publication Critical patent/EP1190722B1/fr
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive plasters or dressings
    • A61F13/023—Adhesive plasters or dressings wound covering film layers without a fluid handling layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/58—Adhesives

Definitions

  • the invention relates to a multilayer dressing, particularly at pressure points Blisters and open blisters inserted on the heel, on the heel of the hand and on the fingers can be.
  • Pressure points, blisters and open blisters on the heel, on the heel of the hand and on the fingers are usually treated with conventional plaster products, which consist of a textile backing material, a pressure-sensitive adhesive layer and a non-woven wound dressing.
  • plaster products consist of a textile backing material, a pressure-sensitive adhesive layer and a non-woven wound dressing.
  • Such proven products are available, for example, from Beiersdorf, for example under the names Hansaplast ® elastic or Hansaplast ® classic.
  • Wound care products based on hydrocolloids have advantages over conventional ones Pave on. These generate a moist wound healing environment that the Wound does not dry out and an optimal environment for quick wound healing generated. Further advantages are the inconspicuousness in the application, secure adherence, Absorbance of exudate (e.g. from a bladder) good cushioning and painless removability.
  • Modern hydrocolloid formulations are based on styrene-isoprene-styrene block polymers with hydrocarbon resins ("hydrocarbon resins”) as tackifiers, mineral oil as plasticizers and CMC as absorbers.
  • hydrocarbon resins hydrocarbon resins
  • These formulations with SIS as a scaffold contain glassy domains (styrene blocks) and thermoplastic domains (isoprene blocks). At room temperature, the glass-like domains create a kind of three-dimensional "cross-linking" structure, which is lifted at a higher temperature.
  • Hydrocolloids also show good "wet tack" in moist conditions, so that they are well suited for use as blister plasters on the heel and palm of the hand, an application site with a relatively high loss of moisture from the skin.
  • a dressing is known from EP 0 264 299 B1, which consists of a water-absorbent sealing pad, which in turn is formed by one or more hydrocolloids.
  • the hydrocolloid (s) are dissolved in or mixed with a binder.
  • the cushion is completely covered by a waterproof cover layer.
  • the pillow is chamfered at least around the outer periphery in such a way that the thickness at the edge does not exceed about a quarter of its maximum thickness.
  • Hydrogels are macromolecular, natural or synthetic substances that are based on a high content of hydrophilic groups are able to absorb water.
  • Hydrogels are used in a variety of ways in wound care, because they protect wounds from drying out, absorb wound secretions, serve as a matrix for all kinds of active substances and also as a basis for colonization with autologous or heterologous skin cells.
  • Hydrogels can be used in the form of foams, among other things. foams to treat skin wounds or surgical wounds are known to those skilled in the art known. Mainly there are polyurethane foams or collagen foams Use.
  • Self-adhesive gel foams are also known to the person skilled in the art. These can be generally fixate well on the skin, but usually have the disadvantage that their water absorption capacity and water retention capacity are severely limited.
  • Hydrophilic foams made from polyurethane gels are also known.
  • WO 88/01878 A1 describes self-adhesive polyurethane foams or polyurethane foam gels, which inter alia can contain copolymerized methacrylates. The making of this Foam gels are made by adding water.
  • Polyurethane gels based on a polyurethane matrix and higher molecular weight polyols are also described in EP 0 057 839 B1.
  • Self-adhesive fabrics made of polyurethane gels are known from EP 0 147 588 B1.
  • the polyurethane gels disclosed in these last two documents are unfoamed.
  • the self-adhesive gels have characteristic isocyanate numbers of 15 to 70 (EP 0 147 588 A2).
  • EP 0 196 364 A2 describes hydrophilic polyurethane foams which are water-absorbent Polymers based on a copolymer of acrylic acid and potassium acetate filled can be and are intended for medical purposes.
  • the polyurethane is based on manufactured by MDI.
  • the polyether used has a minimum functionality of two Hydroxyl groups, preferably two to three hydroxyl groups each.
  • the NCO / OH ratio is stoichiometric. This is not a gel-like polyurethane.
  • Foaming can be done with compressed air or with others that do not react with the isocyanate Gases or with the help of low-boiling solvents.
  • the mix of Absorber with polyether polyol is about 3: 1.
  • the foam has adhesive Properties on wounds that are completely suppressed by aluminized fleece to be able to use it for wound treatment.
  • Foam wound dressings such as those from the Beiersdorf company under the name Cutinova ® thin and Cutinova ® hydro are available. a. described in DE 42 33 289 A1, in DE 196 18 825 A1 and WO 97/43328.
  • the polyurethane gel foam then consists of a polyaddition product of a polyether polyol (Levagel ® from Bayer AG) with an aromatic or aliphatic Diisocyanate (Desmodur ® Bayer AG), in which a polyacrylate superabsorbent powder (Favor ®, Stockhausen) was incorporated.
  • the polyurethane gel can, depending on the ratio from OH equivalents of the polyol to reactive isocyanate groups, weak or can be adjusted to be highly adhesive to the skin.
  • the flat polyurethane gel foam with a thickness of 1 to 6 mm is covered on one side by a polyurethane film. Patches of the appropriate size are punched out of the bale goods.
  • the wound dressing produced in this way surprisingly completely detackifies when absorbing wound fluid and does not show the tendency to disintegrate with strong swelling known from hydrocolloids, which can lead to residues of the hydrocolloid remaining in the wound.
  • the punched-out large-area wound dressings are ideal for treating chronic or difficult-to-heal wounds from patients who need inpatient care.
  • conventional plasters can be used to treat blisters (for example, the Hansaplast ® classic tissue plaster from Beiersdorf), which are only of limited suitability for use as blister plasters for the treatment of pressure points or damaged corneas on strongly contoured parts of the body.
  • blisters for example, the Hansaplast ® classic tissue plaster from Beiersdorf
  • the low elasticity and the tendency for the backing material to roll up at the edges of the plaster prove to be disadvantageous in the case of mechanical stress with a longer wearing period.
  • the plaster is heavily moistened with daily personal care or hand washing and loses its adhesive power. Conventional plasters stand out visually, hinder movements or impair the wearing comfort in the shoe.
  • the object of the invention is to provide a dressing available in the It is able to absorb exudate from pressure points, which cushions well, which is sufficient Moisture is transported from the cornea to the outside through the plaster and which creates a moist wound healing environment.
  • the point lies in the center of the surface in order to achieve a symmetrical appearance of the patch.
  • the bevelling can also be irregular, depending on the needs and application of the patch. This results in a wide variety of shapes.
  • the matrix can be lenticular or hemispherical.
  • the carrier film preferably consists of a transparent, multilayer, water vapor-permeable polyurethane film, which in a further advantageous embodiment has a thickness of 60 to 80 ⁇ m.
  • the advantageous thickness results from the requirement for a rigid material that prevents rolling up under mechanical stress.
  • the top layer consists of a hard polyurethane coating that creates a surface with a particularly low static and sliding friction found to be advantageous for use in the vicinity of pressure points and / or bubbles Has.
  • the adhesive layer with the preferred thickness of 35 to 50 ⁇ m can be regarded as thin.
  • this consists of a skin-friendly PSA made of polyacrylate, into which a tackifier (for example a hydrocarbon resin) is incorporated in order to increase the adhesion to the skin.
  • a tackifier for example a hydrocarbon resin
  • the water vapor permeable outer adhesive layer does not store moisture and protects the central liquid-absorbing adhesive layer from the ingress of Water from the outer edge (sealing) and prevented by a very thin design possible rolling up in the edge area (for example in the shoe).
  • the polyurethane matrix is particularly transparent, highly permeable to water vapor and adhesive.
  • a superabsorbent polymer is preferably used to store liquid incorporated on a polyacrylate basis as a powder.
  • the polyurethane matrix serves as good cushioning (convex shape, maximum thickness preferred approx. 1.6 mm) and as a storage of exudate that comes from the pressure point and / or bladder exit.
  • the ethylene oxide content is in the polyether polyols used according to the invention preferably ⁇ 20% by weight.
  • the polyether polyols are known per se and are described, for example, by Polymerization of epoxides, such as ethylene oxide, propylene oxide, butylene oxide or tetrahydrofuran, with itself or through the addition of these epoxides, preferably from Ethylene oxide and propylene oxide - optionally in a mixture with one another or separately successively - on starter components with at least two reactive hydrogen atoms, such as water, ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol, Glycerin, trimethylolpropane, pentaerythritol, sorbitol or succrose.
  • epoxides such as ethylene oxide, propylene oxide, butylene oxide or tetrahydrofuran
  • Monomeric or trimerized hexamethylene diisocyanate is used as the isocyanate component or by using biuret, uretdione, allophanate groups or by prepolymerization Polyether polyols or mixtures of polyether polyols based on the known Starter components with 2 or> 2 reactive H atoms and epoxides, such as ethylene oxide or propylene oxide with an OH number of ⁇ 850, preferably 100 to 600, modified Hexamethylene diisocyanate used. Modified hexamethylene diisocyanate is preferred. especially by prepolymerizing with polyether diols OH number 200 to 600 modified hexamethylene diisocyanate. Very particularly preferred are modifications of hexamethylene diisocyanate with polyether diols of OH number 200-600, whose residual monomeric hexamethylene diisocyanate content is less than 0.5% by weight lies.
  • the catalysts used for the polyurethane gels according to the invention are the anhydrous ones Polyether polyols a) soluble bismuth (III) carboxylates based on linear, branched, saturated or unsaturated carboxylic acids with 2 to 18, preferably 6 to 18, carbon atoms in question.
  • Bi (III) salts of branched saturated carboxylic acids are preferred tertiary carboxyl groups, such as 2,2-dimethyl-octanoic acid (for example Versatic acids, Shell). Preparations of these bi (III) salts in excess are very suitable Proportions of these carboxylic acids.
  • a solution of 1 mol has proven to be excellent of the Bi (III) salt of Versatic 10-acid (2,2-dimethyloctanoic acid) in excess of 3 mol of this acid with a Bi content of approx. 17%.
  • the catalysts are preferably used in amounts of 0.03 to 0.1% by weight, based on the polyol a) used.
  • antioxidants for the polyurethane gels according to the invention sterically hindered phenolic stabilizers, such as BHT (2,6-di-tert-butyl-4-methylphenol), Vulkanox BKF (2.2 min -methylene-bis- (6-tert-butyl-4-methylphenol) (Bayer AG), Irganox 1010 (pentaerythrityl tetrakis [3- (3,5-di-tert-butyl-4-hydroxyphenyl) propionate]), Irganox 1076 (octadecyl 3- (3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (Ciba-Geigy) or tocopherol (vitamin E). Those of the ⁇ -tocopherol type are preferred used.
  • BHT 2,6-di-tert-butyl-4-methylphenol
  • Vulkanox BKF 2.2 min -methylene-bis- (6
  • the antioxidants are preferably used in amounts of 0.15 to 0.5% by weight, based on the polyol a).
  • the isocyanate index (ratio of the free NCO groups used in the reaction to the free OH groups) of the polyurethane gel compositions according to the invention is in the range from 0.30 to 0.70, preferably in the range, depending on the functionality of the isocyanate and polyol components used from 0.45 to 0.60.
  • the isocyanate index required for gel formation can be easily estimated using the following formula: f ( polyol ) • ( f ( isocyanate ) -1) • identification number ⁇ 2 Key figure ⁇ 2 f (Polyol) • ( f (Isocyanate) -1) f: functionality of the isocyanate or polyol component
  • the polyurethane gel compositions according to the invention are produced by customary processes, as described, for example, in Becker / Braun, Kunststoff-Handbuch, Vol. 7, Polyurethane, p. 121 ff, Carl-Hauser, 1983.
  • the polyurethane gels can be made from those known per se from polyurethane chemistry Starting compounds are prepared by methods known per se, as they are described for example in DE 31 03 499 A1, DE 31 03 500 A1 and EP 0 147 588 A1 become. It is essential, however, that when selecting the yellow-forming components The conditions defined above are observed, otherwise, instead of self-adhesive Gels non-sticky, elastic gels can be obtained.
  • Preferred polyhydroxyl compounds are polyether polyols as described in the above mentioned disclosure documents are mentioned in detail.
  • the polyisocyanate components are both (cyclo) aliphatic and aromatic Suitable isocyanates.
  • Preferred (cyclo) aliphatic polyisocyanates are 1,6-hexamethylene diisocyanate as well as its biurets and trimerisates or hydrogenated diphenylmethane diisocyanate ( "MDI") - types.
  • Preferred aromatic polyisocyanates are those which are obtained by distillation, such as MDI mixtures of 4,4'- and 2,4'-isomers or 4,4'-MDI, as well as tolylene diisocyanate (“TDI”) types.
  • the diisocyanates can be selected, for example, from the group of unmodified ones aromatic or aliphatic diisocyanates or from prepolymerization modified products formed with amines, polyols or polyether polyols become.
  • the polyurethane gels can optionally contain additives known per se from polyurethane chemistry, such as, for example, fillers and short fibers on an inorganic or organic basis, metal pigments, surface-active substances or liquid extenders such as substances with a boiling point above 150 ° C.
  • additives known per se from polyurethane chemistry such as, for example, fillers and short fibers on an inorganic or organic basis, metal pigments, surface-active substances or liquid extenders such as substances with a boiling point above 150 ° C.
  • organic fillers are heavy spar, chalk, gypsum, kieserite, soda, titanium dioxide, cerium oxide, quartz sand, kaolin, carbon black and hollow microspheres.
  • organic fillers for example, powders based on polystyrene, polyvinyl chloride, urea formaldehyde and polyhydrazodicarbonamide can be used.
  • the short fibers are, for example, glass fibers of 0.1-1 mm in length or fibers of organic origin, such as polyester or polyamide fibers.
  • Metal powders such as iron or copper powder, can also be used in the gel formation.
  • the dyes or color pigments known per se in the coloring of polyurethanes on an organic or inorganic basis such as, for example, iron oxide or chromium oxide pigments, pigments based on phthalocyanine or monoazo, can be used.
  • surface-active substances are cellulose powder, activated carbon and silica preparations.
  • additives of polymeric vinyl compounds, polyacrylates and other usual in adhesive technology Copolymers or adhesives based on natural materials up to a content of 10 % By weight, based on the weight of the gel mass, are added.
  • Preferred water-absorbing materials are water-absorbing salts of polyacrylates and their copolymers known as superabsorbers, in particular the sodium or potassium salts. They can be non-networked or networked and are also available as commercial products. Products such as those disclosed in DE 37 13 601 A1 and also superabsorbents of the new generation with only small proportions of dry water and high swelling capacity under pressure are particularly suitable. Preferred products are weakly crosslinked polymers based on acrylic acid / sodium acrylate. Such sodium polyacrylates are available as Favor 22-SK (Chemische Fabrik Stockhausen GmbH, Germany). Other absorbers, for example carboxymethyl cellulose and karaya, are also suitable.
  • the degree of foaming can be determined by the amount of foaming agent incorporated vary within wide limits.
  • the self-adhesive product through a siliconized paper or a particularly siliconized film covered, so that the adhesive side during the Storage is protected.
  • the transparent dressing according to the invention indicates long-lasting adhesive power highly contoured corneal surfaces of the human body by the special Product structure is achieved.
  • the bandage shows good cushioning properties without impairment comfort in the shoe thanks to the special convex plaster shape.
  • the rolling up in the shoe of the plaster due to mechanical stress is sufficient by a thick and rigid carrier material prevented.
  • Absorption of exudate from pressure points is achieved by means of an adhesive polyurethane matrix containing superabsorbers. Adequate moisture transport from the cornea through the plaster to the outside takes place by combining suitable components of the carrier and adhesive, while generating a moist wound healing environment.
  • the new association is characterized by a significantly longer wearing time, very good Comfort properties, residue-free removability and inconspicuous appearance compared to conventional plasters, therefore shows optimal adhesion to areas of the cornea (Heel or heel of the hand) due to the central, highly cushioning, liquid-absorbing, weakly adhesive pressure-sensitive adhesive zone and the strongly adhesive, non-absorbent outer zone and the specially designed water vapor permeable Support material.
  • Figure 1 and Figure 2 illustrate the preferred geometric shape of the dressing, as it is used in particular for blister plasters.
  • the plaster has an ellipsoidal shape and consists of a carrier film 1 which is coated over its entire area with an adhesive layer 2.
  • the entire periphery of the adhesive layer 2 is not covered with the polyurethane matrix 3. This results in two concentric zones of chemically different adhesives 2, 3, which differ in terms of adhesiveness, absorption capacity and cushioning properties.
  • the polyurethane matrix 3 is essentially semi-convex, and is therefore comparable to a semi-convex lens.
  • the patch is covered with siliconized paper 4 to prevent contamination or to avoid contamination of the adhesive 2 or the matrix 3.
  • Example 1 Association, in particular for supplying pressure points and blisters
  • the backing material of the patch consists of a multi-layer 50 ⁇ m thick film a polyester urethane (Impranil-Type, Bayer AG, Leverkusen).
  • the layer structure is produced by repeated casting of an approximately 20 g / m 2 polyester urethane layer on an approximately 100 ⁇ m thick PE film (Waloplast, Wolf Walsrode).
  • the composition of the polyether urethane is successively changed in such a way that the proportion of soft polyether blocks increases with each stroke and thus the hardest stroke as the outer top coat closes the pavement to the outside.
  • the PE film is removed from the PU carrier in a later processing step.
  • the acrylate PSA is spread on a siliconized paper and scraped off.
  • the full-surface coating is then in the drying tunnel at temperatures from 60 to 100 ° C dried.
  • the carrier (composite) is laminated on after the drying tunnel.
  • the composite product is exposed to radiation of 11 to 12 kW at 254 nm for approx. 1 s irradiated to crosslink the adhesive.
  • a type C acrylate PSA with a basis weight of 50 g / m 2 is used , consisting of a copolymer of ethylhexyl acrylate, n-butyl acrylate and acrylic acid.
  • An adhesive resin from the group of the C 5 hydrocarbon resins is added to the copolymer (for example Escorez 5340 from Exxon).
  • Physical data of the PSA on Hostaphan (PET) method unit Acrylate PSA type C + Escorez 5340 Comparative example: Type C acrylate PSA application rate g / m 2 50 50 Adhesive force steel / peel-force N / cm 4.0 3.1 Tack (rolling ball) cm 5.3 6.5
  • Type D combination carrier-pressure sensitive adhesive acrylate pressure-sensitive adhesive type C + Escorez 5340 on 60g / m 2 carrier (type A)
  • Type E combination of carrier and pressure sensitive adhesive acrylate PSA type C + Escorez 5340 on 80 g / m 2 carrier (type B) application rate g / m 2 56 56 Adhesive force steel / (peel-force) N / cm 6.7 7.1 Water vapor permeability g / (m 2
  • the coated carrier is placed in a casting mold which has a concave, oval recess.
  • the depression is approx. 1.6 mm deep in the center of the oval and gradually decreases towards the edges.
  • the coated backing is placed with the PSA coating on the upper side in the casting mold and 0.7 g of the reactive polyurethane mass (Levagel, diisocyanate, catalyst, superabsorber; index 45 to 55) is applied in the middle of the cavity.
  • the composite is covered with a siliconized, PE coated paper and loaded with a weight until the final hardening. After curing, the PE film is removed and the outer plaster edge oval is punched out concentrically around the central absorber zone.
  • the result is a self-adhesive wound care product with an outer, strongly adhesive zone measuring 43 x 68 mm and an inner, cushioning and liquid-absorbing zone measuring 25 x 46 mm, which generates a moist wound healing environment.
  • the water vapor permeable polyurethane backing provides a barrier against water and bacteria and prevents maceration of the skin under the patch.
  • the carrier material of the patch consists of a 35 ⁇ m thick film of a polyester urethane (Impranil-Type, Bayer AG, Leverkusen). This is produced by repeatedly pouring an approx. 20 g / m 2 polyester urethane layer on an approx. 100 ⁇ m thick PE film (Waloplast, Wolf Walsrode), which is removed when the plaster is applied.
  • a polyester urethane Impranil-Type, Bayer AG, Leverkusen
  • the acrylate PSA is spread on a siliconized paper and scraped off.
  • the full-surface coating is then in the drying tunnel at temperatures from 60 to 100 ° C dried.
  • the carrier (composite) is laminated on after the drying tunnel.
  • the composite product is exposed to radiation of 11 to 12 kW at 254 nm for approx. 1 s irradiated to crosslink the adhesive.
  • a type C acrylate PSA with a basis weight of 50 g / m 2 is used , consisting of a copolymer of ethylhexyl acrylate, n-butyl acrylate and acrylic acid.
  • the physical data of the PSA can be found in Table 2 under point b) in Example 1.
  • Type G combination carrier - PSA Type C acrylate PSA on 40g / m 2 carrier (Type F) application rate g / m 2 38
  • the coated carrier is placed in a casting mold which has a concave, oval recess.
  • the depression is approx. 1.3 mm deep in the center of the oval and gradually decreases towards the edges.
  • the coated carrier is placed with the pressure-sensitive adhesive coating on the upper side in the casting mold and 1.6 g of the reactive polyurethane mass (Levagel, diisocyanate, catalyst, superabsorbent, titanium dioxide; index 45 to 55) are applied in the middle of the cavity.
  • the composite is covered with a siliconized, PE coated paper and loaded with a weight until the final hardening. After curing, the PE film is provided with a pulling aid and the oval plaster edge is punched out concentrically around the central absorber zone.
  • the peeling aid is used to remove the PE film from the PU carrier after the plaster has been stuck to the wound.
  • the result is a self-adhesive wound care product with an outer, strongly adhesive zone measuring 66 x 110 mm and an inner, cushioning and liquid-absorbing zone measuring 40 x 80 mm, which generates a moist wound healing environment.
  • the absorption zone appears milky due to the titanium dioxide and thus covers the wound not only physically but also visually.
  • the water vapor permeable polyurethane backing provides a barrier against water and bacteria and prevents maceration of the skin under the patch.
EP01120367A 2000-09-22 2001-08-25 Pansement Revoked EP1190722B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10047673 2000-09-22
DE10047673A DE10047673A1 (de) 2000-09-22 2000-09-22 Verband

Publications (3)

Publication Number Publication Date
EP1190722A2 true EP1190722A2 (fr) 2002-03-27
EP1190722A3 EP1190722A3 (fr) 2003-04-09
EP1190722B1 EP1190722B1 (fr) 2006-04-19

Family

ID=7657689

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01120367A Revoked EP1190722B1 (fr) 2000-09-22 2001-08-25 Pansement

Country Status (6)

Country Link
US (1) US6822132B2 (fr)
EP (1) EP1190722B1 (fr)
AT (1) ATE323515T1 (fr)
AU (1) AU6997001A (fr)
DE (2) DE10047673A1 (fr)
ES (1) ES2261307T3 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1190723A2 (fr) * 2000-09-22 2002-03-27 Beiersdorf AG Pansement adhésif avec zone adhésive couvrant la blessure
WO2002102358A1 (fr) * 2001-05-02 2002-12-27 Beiersdorf Ag Pansement presentant une surface pourvue d'un principe actif
WO2005004936A1 (fr) * 2003-07-08 2005-01-20 Beiersdorf Ag Pansement applicable sur la peau ou sur des plaies, renfermant des substances encapsulees favorisant la guerison des plaies et/ou pour soins cutanes
WO2013034277A1 (fr) * 2011-09-06 2013-03-14 Dr. Kenndoff GmbH & Co. KG Utilisation d'un pansement plat flexible semi-occlusif pour le traitement de plaies chez les animaux
WO2018060958A1 (fr) * 2016-09-30 2018-04-05 Adrian Giger Pansement de réduction de cicatrice
US10549283B2 (en) 2016-12-21 2020-02-04 Sandvik Intellectual Property Ab Jaw crusher retraction assembly

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455710B2 (en) 1997-09-22 2013-06-04 Argentum Medical, Llc Conductive wound dressings and methods of use
US8801681B2 (en) 1995-09-05 2014-08-12 Argentum Medical, Llc Medical device
US7214847B1 (en) 1997-09-22 2007-05-08 Argentum Medical, L.L.C. Multilayer conductive appliance having wound healing and analgesic properties
US6861570B1 (en) 1997-09-22 2005-03-01 A. Bart Flick Multilayer conductive appliance having wound healing and analgesic properties
US5814094A (en) 1996-03-28 1998-09-29 Becker; Robert O. Iontopheretic system for stimulation of tissue healing and regeneration
US20050027227A1 (en) * 2003-04-28 2005-02-03 Cynthia Dumas Disposable, water resistant cover for medical applications
DE10328261B4 (de) * 2003-06-23 2007-10-25 Beiersdorf Ag Desinfizierende Auflage mit Silberbeschichtung und ihre Verwendung
EP1638620B2 (fr) * 2003-06-23 2018-04-25 Beiersdorf AG Pansement antimicrobien
US8951551B2 (en) * 2005-08-31 2015-02-10 Board Of Regents, The University Of Texas System Multiribbon nanocellulose as a matrix for wound healing
EP1943992B1 (fr) * 2007-01-12 2012-02-22 The Procter & Gamble Company Noyau absorbant avec structure améliorée
AU2009214596B2 (en) * 2008-02-14 2014-07-31 Avery Dennison Corporation Fluid absorbent adhesive articles
US20110087144A1 (en) * 2009-10-12 2011-04-14 Lynda Lee Disposable shower protective cover
DE202009015670U1 (de) * 2009-11-30 2011-04-14 Mcairlaid's Vliesstoffe Gmbh & Co. Kg Absorptionskörper zur Auflage auf Wunden
US8381498B2 (en) 2011-07-20 2013-02-26 Marc Irwin Epstein Method of manufacturing a dressing package
US10456497B2 (en) 2014-09-10 2019-10-29 C. R. Bard, Inc. Protective dressing for skin-placed medical device
BR102019003047A2 (pt) * 2019-02-14 2020-10-06 Ana Laura Tammy Miura Curativo para micropigmentação
DE102019116249A1 (de) * 2019-06-14 2020-12-17 Technogel Gmbh Hydrokolloid-Wundverband

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0147588A1 (fr) * 1983-11-17 1985-07-10 Bayer Ag Objets plats autoadhésifs, procédé pour les fabriquer et utilisation
EP0264299A2 (fr) * 1986-10-17 1988-04-20 Coloplast A/S Bandage
WO1992005755A1 (fr) * 1990-10-01 1992-04-16 Jensen Ole R Pansement pour plaie a couche adhesive profilee
EP0919211A2 (fr) * 1997-11-27 1999-06-02 Beiersdorf Aktiengesellschaft Pansement
EP1190723A2 (fr) * 2000-09-22 2002-03-27 Beiersdorf AG Pansement adhésif avec zone adhésive couvrant la blessure

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377159A (en) * 1981-06-29 1983-03-22 Minnesota Mining And Manufacturing Company Pressure bandages and methods for making the same
DE3685227D1 (de) * 1985-01-04 1992-06-17 Squibb & Sons Inc Wundverband.
AU597740B2 (en) * 1986-09-20 1990-06-07 Smith & Nephew Associated Companies Plc Adhesive dressing
US5409472A (en) * 1989-08-03 1995-04-25 Smith & Nephew Plc Adhesive polymeric foam dressings
US5264218A (en) * 1989-10-25 1993-11-23 C. R. Bard, Inc. Modifiable, semi-permeable, wound dressing
US5591447A (en) * 1990-10-01 1997-01-07 Hollister Incorporated Wound dressing having a contoured adhesive layer
AU692424B2 (en) * 1992-10-02 1998-06-11 Beiersdorf Aktiengesellschaft Hydrophilic polyurethane gel foams, particularly for treating deep wounds, wound dressing based on hydrophilic polyurethane gel foams and method of manufacture
CA2149875A1 (fr) * 1992-11-21 1994-06-09 William John Ward Pansements pour plaies
EP0731680A1 (fr) * 1993-12-01 1996-09-18 Smith & Nephew P.L.C. Pansement pour lesions
US5512041A (en) * 1994-10-07 1996-04-30 Scott Health Care Wound dressing for promoting moist wound healing
FR2781679B1 (fr) * 1998-07-31 2001-06-08 Lhd Lab Hygiene Dietetique Nouveau pansement hydrocellulaire etanche et utilisation d'une masse adhesive hydrocolloide
DE19901078C1 (de) * 1999-01-14 2000-02-17 Polaschegg Hans Dietrich Verfahren und Vorrichtung zur Erkennung von Stenosen bei der extrakorporalen Blutbehandlung
US6264976B1 (en) * 1999-11-29 2001-07-24 3M Innovative Properties Company Absorbent pad dressing frame delivery system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0147588A1 (fr) * 1983-11-17 1985-07-10 Bayer Ag Objets plats autoadhésifs, procédé pour les fabriquer et utilisation
EP0264299A2 (fr) * 1986-10-17 1988-04-20 Coloplast A/S Bandage
WO1992005755A1 (fr) * 1990-10-01 1992-04-16 Jensen Ole R Pansement pour plaie a couche adhesive profilee
EP0919211A2 (fr) * 1997-11-27 1999-06-02 Beiersdorf Aktiengesellschaft Pansement
EP1190723A2 (fr) * 2000-09-22 2002-03-27 Beiersdorf AG Pansement adhésif avec zone adhésive couvrant la blessure

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1190723A2 (fr) * 2000-09-22 2002-03-27 Beiersdorf AG Pansement adhésif avec zone adhésive couvrant la blessure
EP1190723A3 (fr) * 2000-09-22 2003-04-09 Beiersdorf AG Pansement adhésif avec zone adhésive couvrant la blessure
EP1695721A1 (fr) * 2000-09-22 2006-08-30 Beiersdorf Aktiengesellschaft Pansement adhésif avec zone adhésive couvrant la blessure
WO2002102358A1 (fr) * 2001-05-02 2002-12-27 Beiersdorf Ag Pansement presentant une surface pourvue d'un principe actif
WO2005004936A1 (fr) * 2003-07-08 2005-01-20 Beiersdorf Ag Pansement applicable sur la peau ou sur des plaies, renfermant des substances encapsulees favorisant la guerison des plaies et/ou pour soins cutanes
WO2013034277A1 (fr) * 2011-09-06 2013-03-14 Dr. Kenndoff GmbH & Co. KG Utilisation d'un pansement plat flexible semi-occlusif pour le traitement de plaies chez les animaux
CN103874515A (zh) * 2011-09-06 2014-06-18 肯道夫博士有限责任两合公司 半闭合式柔韧型平面伤口贴剂用于处理动物伤口的用途
US9681934B2 (en) 2011-09-06 2017-06-20 Dr. Kenndoff GmbH & Co. KG Use of a semi-occlusive flexible flat wound dressing for treating wounds in animals
WO2018060958A1 (fr) * 2016-09-30 2018-04-05 Adrian Giger Pansement de réduction de cicatrice
US11510821B2 (en) 2016-09-30 2022-11-29 Adrian Giger Scar reduction bandage
US10549283B2 (en) 2016-12-21 2020-02-04 Sandvik Intellectual Property Ab Jaw crusher retraction assembly

Also Published As

Publication number Publication date
AU6997001A (en) 2002-03-28
DE10047673A1 (de) 2002-04-11
US20020156411A1 (en) 2002-10-24
US6822132B2 (en) 2004-11-23
EP1190722B1 (fr) 2006-04-19
DE50109534D1 (de) 2006-05-24
ES2261307T3 (es) 2006-11-16
EP1190722A3 (fr) 2003-04-09
ATE323515T1 (de) 2006-05-15

Similar Documents

Publication Publication Date Title
EP1190722B1 (fr) Pansement
EP1190723B1 (fr) Pansement adhésif avec zone adhésive couvrant la blessure
EP0665856B1 (fr) Gels moussants hydrophiles de polyurethane, notamment pour le traitement de plaies profondes, pansements a base de gels moussants hydrophiles de polyurethane et procede de fabrication
EP1830896B1 (fr) Mousses polyurethane resistantes a l'infection, leur procede de production et leur utilisation dans des pansements a action antiseptique
EP1648529B1 (fr) Pansement applicable sur la peau ou sur des plaies, renfermant des substances encapsulees favorisant la guerison des plaies et/ou pour soins cutanes
US6103369A (en) Multi-layered dressing
US6680113B1 (en) Multi-layered dressing
US4914173A (en) Adhesives, their preparation and use
DE60124118T2 (de) Mehrschichtiger absorbierender wundverband
EP2179749B1 (fr) Mousses de gel de polyuréthane
EP1490118A1 (fr) Pansement reducteur de cicatrices
DE4233289A1 (de) Hydrophile Polyurethanschaumgele und Verfahren zu deren Herstellung
DE4308445A1 (de) Wundverbände auf Basis hydrophiler Polyurethangelschäume und Verfahren zu deren Herstellung
WO2004064879A1 (fr) Pansement muni d'une compresse imprimee et d'une pellicule de fixation transparente
EP0715526B1 (fr) Article de soins de plaies a capacite d'absorption selective
EP1203572A2 (fr) Méthode de fabrication d'un pansement multicouche sur une couche de support à base de polyuréthane

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20031009

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20050210

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060419

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060419

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060419

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060419

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REF Corresponds to:

Ref document number: 50109534

Country of ref document: DE

Date of ref document: 20060524

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060719

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060719

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20060711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060831

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060919

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2261307

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: PAUL HARTMANN AG

Effective date: 20070118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060825

BERE Be: lapsed

Owner name: BEIERSDORF A.G.

Effective date: 20060831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060419

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060825

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20080814

Year of fee payment: 8

Ref country code: DE

Payment date: 20080831

Year of fee payment: 8

Ref country code: ES

Payment date: 20080828

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060419

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20080813

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080821

Year of fee payment: 8

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

27W Patent revoked

Effective date: 20090315

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20090315